Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes

被引：0
|
作者：
Ma, J. [1 ]
Yang, W. [2 ]
Hong, T. [3 ]
Liu, M. [4 ]
Miao, H. [5 ]
Peng, Y. [6 ]
Wang, C. [7 ]
Xu, X. [8 ]
Yang, T. [9 ]
Liu, W. [10 ]
Nielsen, A. Moeller [11 ]
Pan, L. [10 ]
Weigang, Z. [12 ]
机构：
[1] Nanjing First Hosp, Nanjing, Jiangsu, Peoples R China
[2] China Japan Friendship Hosp, Beijing, Peoples R China
[3] Peking Univ, Hosp 3, Beijing, Peoples R China
[4] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
[5] Nanjing Med Sch, Affiliated Hosp 2, Nanjing, Jiangsu, Peoples R China
[6] Shanghai First Peoples Hosp, Shanghai, Peoples R China
[7] Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China
[8] Nanjing Mil Command, Fuzhou Gen Hosp, Nanjing, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[10] Novo Nordisk, Beijing, Peoples R China
[11] Novo Nordisk, Soborg, Denmark
[12] Peking Union Med Coll Hosp, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
835
引用
收藏
页码：S410 / S411
页数：2
相关论文
共 50 条
  • [1] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    [J]. DIABETES, 2018, 67
  • [2] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [3] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [4] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [5] Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial
    Franek, Edward
    Haluzik, Martin
    Canecki-Varzic, Silvija
    Sargin, Mehmet
    Macura, Stanislava
    Zacho, Jeppe
    Christiansen, Jens Sandahl
    [J]. DIABETES, 2014, 63 : A225 - A225
  • [6] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [7] Efficacy and safety of insulin degludec/insulin aspart vs biphasic insulin aspart 30: an international randomised trial in adults with type 2 diabetes fasting during Ramadan
    Hassanin, M.
    Echtay, A.
    Malek, R.
    Omar, M.
    Shaikh, S.
    Fita, E. G.
    Kaplan, K.
    Kamaruddin, N.
    [J]. DIABETOLOGIA, 2017, 60 : S75 - S75
  • [8] Use of a New Basal Insulin with a Bolus Boost (IDegAsp) in Type 2 Diabetes: Comparison with Biphasic Insulin Aspart 30 (BIAsp 30)
    Vaag, Allan
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine V.
    Niskanen, Leo
    [J]. DIABETES, 2011, 60 : A313 - A313
  • [9] A Thrice Daily Regimen with Biphasic Insulin Aspart 50 Is More Effective and as Safe as Twice Daily Biphasic Insulin Aspart 30 in Chinese Subjects with Type 2 Diabetes
    Gao, Yan
    [J]. DIABETES, 2010, 59 : A153 - A153
  • [10] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial (vol 167, pg 287, 2012)
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (03) : 453 - 453
12345